Evidence map›Paper›PMID 40511809›Full record

ReviewAnti-cancer agents in medicinal chemistry2026

Exploring the Therapeutic Potential of

Tohfa Siddiqui, Md Nasar Mallick, Vikram Sharma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Anti-cancer agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tohfa SiddiquiDepartment of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, India.
Md Nasar MallickDepartment of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, India.
Vikram SharmaDepartment of Pharmacy, Galgotias College of Pharmacy, Knowledge Park 2, Greater Noida, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is one of the most common malignancies affecting women worldwide. It is a complex, heterogeneous disease, classified into several subtypes, including hormone receptor-positive and triple-negative breast cancer (TNBC), each with distinct therapeutic challenges. TNBC, in particular, is characterized by its aggressive nature and lack of targeted therapies due to the absence of estrogen, progesterone, and HER2 receptors. This review explores the potential of natural plant-based compounds, especially focusing on Clove Basil (Ocimum sanctum) and

Indexed as

Antineoplastic Agents, PhytogenicBreast NeoplasmsOcimum sanctumPlant ExtractsAnimalsApoptosisCell ProliferationDrug Screening Assays, AntitumorFemaleHumansAntineoplastic Agents, PhytogenicPlant ExtractsBreast cancerherbal approachholy basilmitochondrial pathway.Ocimum sanctumPhanera variegata

Identifiers

PMID40511809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.